Single-Cell Omics Patents: Top Companies & Filing Trends 2026
- 21.7% concentration at the top. The five leading assignees account for 1,884 of 8,673 records in scope, so a large share of the field still sits outside any single leader's claim set.
- Filing cooled after a 2021 peak. Activity ran from 906 records in 2021 to 608 in 2024, a -33% swing over that span, though the newest years understate themselves due to publication lag.
- Bioinformatics claims remain thin. G16B (bioinformatics) appears on just 12.6% of records versus 46.7% for core sequencing/measurement claims under C12Q, leaving computational layers comparatively open.
Filing growth compares 2021 (906 records) with 2024 (608) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 8,673 records in scope (CR5), not by the ranked leaders only.
What the single-cell omics patent record shows
Single-cell omics covers the methods and systems for isolating, sequencing and analysing individual cells rather than bulk tissue samples — droplet partitioning, barcoding, sequence alignment pipelines and the downstream bioinformatics that turn reads into calls on gene expression or genomic variation. The 8,673 records captured here span filings from 2015 through the 2026 cut-off, combining core molecular biology claims with the data-processing layer built on top of them. Coverage is broad enough to include both wet-lab platform patents and the software methods that interpret their output, which is why IPC classes overlap heavily rather than partitioning the field cleanly.
Filing offices skew toward the United States, followed by Europe and the WIPO PCT route, with meaningful volume also filed into Australia, Canada and Israel — a pattern consistent with a field where platform vendors file broadly to protect instrument and reagent claims across major biotech markets.
Filing trend and technology composition
Two views of the same 8,673-record dataset: how filing volume moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017–2026
Annual records rose from 531 in 2017 to a peak of 906 in 2021, then eased to 608 by 2024 (-33% over that three-year span) before the 2025-2026 count of 62 reflects publication lag rather than a real drop-off; the most recent one to two years will fill in as pending applications publish.
IPC subclass composition (share of 8,673 records)
C12Q (measuring/testing involving enzymes or DNA) touches 46.7% of records and C12N (microorganisms and genetic engineering) 38.2%, confirming that most claims still anchor on the molecular assay itself. A61K medicinal preparations (31.6%) and G01N material analysis (24.1%) follow, while G16B bioinformatics (12.6%) and C40B combinatorial libraries (6.0%) are the thinnest bands, sitting well below the wet-lab classes despite covering the computational and screening layers that increasingly determine commercial differentiation.
Shares are the percentage of the 8,673 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Single-Cell Omics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about single-cell omics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in the corpus
Denoising and gene filtering for single cell sequencing data using graph mining (US20240386999A1)
The system encodes a single-cell sequencing dataset into a graph with cell nodes, gene nodes and edges representing measured gene expression levels. A node embedding algorithm and link prediction model identify edges that should have been captured but were missed in the raw dataset, while a community detection algorithm groups highly associated nodes. Specificity gene scores computed from those communities are then used to filter genes with weaker association, denoising the dataset before downstream analysis.Filed by Accenture Global Solutions, published 2024-11-21 — notable as a non-life-sciences-native filer working the computational denoising layer.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20120220494A1 | Compositions and methods for molecular labeling | 716 |
| 2 | US20210090694A1 | Data based cancer research and treatment systems and methods | 715 |
| 3 | WO2015031691A1 | Massively parallel single cell analysis | 676 |
| 4 | US20100022414A1 | Droplet Libraries | 607 |
| 5 | WO2012083225A2 | System and methods for massively parallel analysis of nycleic acids in single cells | 571 |
| 6 | US20120316074A1 | Methods and compositions for nucleic acid analysis | 569 |
| 7 | US20150299784A1 | Massively parallel single cell analysis | 536 |
| 8 | US20130116130A1 | Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Label-Tags | 454 |
| 9 | WO2007147079A2 | Rare cell analysis using sample splitting and DNA tags | 448 |
| 10 | US20120270212A1 | Methods for Non-Invasive Prenatal Ploidy Calling | 431 |
Citation counts inside a searched corpus favour older filings that have had more years to accumulate references; treat them as a signal of influence on the field's early architecture, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the concentration and momentum data
The ranking and trend figures point to a field where a handful of research institutions and platform vendors hold a meaningful but not dominant share, and where growth has cooled from a clear 2021 peak.
Leadership is real but not a lock
The top five assignees combine for 1,884 of the 8,673 records in scope — 21.7% of the field. The leader alone holds 436 records, with the fifth-place holder at 321, so no single organisation controls the space outright, and a long tail of the remaining 95 ranked assignees plus unranked filers hold the rest.
Post-peak cooling, not collapse
Filings rose from 531 in 2017 to a peak of 906 in 2021, then declined to 608 by 2024 — a -33% move over that span. Recent-year momentum data for several leading assignees shows year-on-year declines as well, though the very newest years are still filling in behind an 18-month publication lag.
Assay claims dominate, software claims lag
C12Q and C12N together anchor most of the corpus, reflecting heavy claim density on sequencing chemistry, library prep and genetic engineering methods. G16B bioinformatics sits at just 12.6% of records, a gap worth noting given how much commercial value in single-cell platforms now sits in the software pipeline rather than the wet lab.
A small number of tight research partnerships
Only 10 co-assignee pairs appear in the data, and the strongest single pairing accounts for 356 co-filed records, with a second pairing at 193 and a third at 115. This is a field where institutional collaboration is concentrated in a few durable partnerships rather than spread widely.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to single-cell omics patent landscape, with the prior art for and against each one.
Who is filing, and where momentum is shifting
The ranked assignee list spans academic research institutes, sequencing-platform vendors and biotech therapeutics developers, with recent-year momentum trending down across most of the visible leaders.
The single largest filer by record count
The top-ranked assignee holds 436 records, ahead of the fifth-place holder at 321 and the tenth-place holder at 231 — a gradual taper rather than a sharp cliff, typical of a field anchored by a few long-running academic research programmes.
Recent-year filing is down across most leading assignees
Several of the most active historical filers show sharp year-on-year declines in the latest tracked year — for example a fall from prior levels to just 1-6 records among some of the largest names. This reads as a maturing filing posture from early movers rather than exit, since publication lag means the newest filings have not fully surfaced yet.
Partnerships cluster around a few institutions
Co-filing is limited to 10 identified pairs, with the strongest at 356 shared records. This suggests most assignees file independently, and joint IP tends to form around long-standing academic-industry or academic-academic relationships rather than one-off collaborations.
| Assignee | Recent year | YoY |
|---|---|---|
| BioNTech SE | 6 | -14% |
| Natera Inc | 4 | -80% |
| The Board of Trustees of the Leland Stanford Junior University | 3 | -70% |
| 10x Genomics Inc | 2 | -88% |
| TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH | 2 | -60% |
| The Broad Institute Inc | 1 | -83% |
| Massachusetts Institute of Technology | 1 | -67% |
| President and Fellows of Harvard College | 0 | -100% |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing strategy or identifying open claim space.
Check freedom-to-operate against the top holders
With 21.7% of records held by five assignees, a targeted clearance search against those portfolios is a faster first pass than reviewing the full 8,673-record set.
Run a clearance search in EurekaTrack the bioinformatics gap
G16B claims sit at 12.6% of records against 46.7% for core assay claims — a wide enough gap to warrant a closer look at what is and is not already claimed in the computational layer.
Explore G16B filings in EurekaWatch momentum shifts among leading filers
Recent-year declines among several top assignees may signal a shift in filing strategy rather than reduced R&D activity; monitoring new applications as they publish will clarify which.
Set up assignee monitoring in EurekaCommon questions on single-cell omics patents
The dataset ranks 100 assignees by record count, with the leader holding 436 of the 8,673 records in scope and the fifth-place holder at 321. Together the top five assignees account for 1,884 records, or 21.7% of the field, which means concentration is meaningful but far from total control. The remaining records are spread across the other 95 ranked assignees plus a long tail of smaller and unranked filers, so a competitive review should not stop at the leader alone.
Filing volume rose from 531 records in 2017 to a peak of 906 in 2021, then fell to 608 by 2024 — a -33% change over that three-year span. That decline should be read as a genuine post-peak cooling rather than a collapse, since 2024 is the most recent year with a largely complete publication record. Counts for 2025 and 2026 in the dataset are still artificially low because patent publication typically lags filing by around 18 months.
C12Q, covering measuring and testing methods involving enzymes and DNA, appears on 46.7% of the 8,673 records, making it the single largest IPC subclass in the corpus. C12N (microorganisms and genetic engineering) follows at 38.2%, and A61K (medicinal preparations) at 31.6%. Bioinformatics-specific claims under G16B are comparatively rare at 12.6%, indicating that most patent activity still centres on the molecular assay rather than the downstream computational analysis.
The clearest signal is the gap between core assay classes and the computational layer: C12Q and C12N each cover well over a third of records, while G16B bioinformatics sits at just 12.6% and C40B combinatorial libraries at 6.0%. That gap suggests methods for graph-based denoising, multi-omic data alignment and automated cell-typing pipelines are less densely claimed than the underlying sequencing chemistry, though any specific filing still needs its own clearance search before relying on this as a strategy.
With the top five assignees holding 21.7% of the 8,673 records and the top ten holding 36.3%, this field shows moderate concentration — enough that a handful of institutions shape the core claim landscape, but not so much that new entrants face a single dominant blocker. Co-assignee data reinforces this: only 10 identified collaboration pairs exist in the dataset, with the strongest pairing covering 356 shared records, pointing to a small number of durable academic-industry partnerships rather than field-wide consolidation.
Research Single-Cell Omics Patent Landscape in depth with Eureka
Go past this page: query the whole single-cell omics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.